CY1105253T1 - Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως - Google Patents

Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως

Info

Publication number
CY1105253T1
CY1105253T1 CY20051101521T CY051101521T CY1105253T1 CY 1105253 T1 CY1105253 T1 CY 1105253T1 CY 20051101521 T CY20051101521 T CY 20051101521T CY 051101521 T CY051101521 T CY 051101521T CY 1105253 T1 CY1105253 T1 CY 1105253T1
Authority
CY
Cyprus
Prior art keywords
metabolitan
eteopolycyclic
glutaminate
receptor
compounds
Prior art date
Application number
CY20051101521T
Other languages
Greek (el)
English (en)
Inventor
Bradford C. Van Wagenen
Thomas M. Stormann
Scott T. Moe
Susan M. Sheehan
Donald A. Mcleod
Daryl L. Smith
Methvin Benjamin Isaac
Abdelmalik Slassi
Original Assignee
Nps Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22530400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105253(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Pharmaceuticals, Inc. filed Critical Nps Pharmaceuticals, Inc.
Publication of CY1105253T1 publication Critical patent/CY1105253T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CY20051101521T 1999-08-19 2005-12-09 Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως CY1105253T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14946499P 1999-08-19 1999-08-19
PCT/US2000/022618 WO2001012627A1 (en) 1999-08-19 2000-08-18 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
CY1105253T1 true CY1105253T1 (el) 2010-03-03

Family

ID=22530400

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20051101521T CY1105253T1 (el) 1999-08-19 2005-12-09 Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως

Country Status (27)

Country Link
EP (1) EP1210344B1 (OSRAM)
JP (2) JP3790472B2 (OSRAM)
KR (1) KR100875222B1 (OSRAM)
CN (1) CN1313465C (OSRAM)
AT (1) ATE307129T1 (OSRAM)
AU (1) AU780191B2 (OSRAM)
BG (1) BG65586B1 (OSRAM)
BR (1) BR0013427A (OSRAM)
CA (1) CA2381975A1 (OSRAM)
CY (1) CY1105253T1 (OSRAM)
CZ (1) CZ2002599A3 (OSRAM)
DE (1) DE60023318T2 (OSRAM)
DK (1) DK1210344T3 (OSRAM)
EE (1) EE200200079A (OSRAM)
ES (1) ES2250177T3 (OSRAM)
HU (1) HUP0202757A3 (OSRAM)
IL (2) IL148157A0 (OSRAM)
IS (1) IS6275A (OSRAM)
MX (1) MXPA02001764A (OSRAM)
NO (1) NO322460B1 (OSRAM)
NZ (1) NZ517221A (OSRAM)
PL (1) PL353825A1 (OSRAM)
RU (1) RU2296127C9 (OSRAM)
SK (1) SK2512002A3 (OSRAM)
UA (1) UA75871C2 (OSRAM)
WO (1) WO2001012627A1 (OSRAM)
ZA (1) ZA200201358B (OSRAM)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UA74419C2 (uk) * 2001-02-21 2005-12-15 Ен Пі Ес Фармасьютікалс, Інк. Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
EP1392363B1 (en) 2001-04-02 2006-09-20 Brown University Research Foundation Use of mGLuR5 antagonists in the manufacture of a medicament in the treatment of Fragile X syndrome, Autism and Mental Retardation
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
CA2469821C (en) * 2001-12-18 2009-10-20 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
AU2002359714B2 (en) * 2001-12-18 2006-12-21 Merck Sharp & Dohme Corp. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1458385A4 (en) * 2001-12-19 2005-12-21 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
US7592337B2 (en) * 2002-03-12 2009-09-22 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
US20040132726A1 (en) * 2002-08-09 2004-07-08 Astrazeneca Ab And Nps Pharmaceuticals, Inc. New compounds
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7268151B2 (en) * 2003-04-04 2007-09-11 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
EP1625123A4 (en) * 2003-05-15 2007-08-29 Merck & Co Inc 3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
BRPI0418149A (pt) * 2003-12-24 2007-04-17 Prosidion Ltd derivados heterocìclicos como agonistas do receptor de gprc
NZ548693A (en) * 2004-02-18 2010-05-28 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
SI1716152T1 (sl) * 2004-02-18 2008-12-31 Astrazeneca Ab Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
JP4803034B2 (ja) * 2004-06-30 2011-10-26 Ｍｓｄ株式会社 ビアリール誘導体
KR100621192B1 (ko) * 2004-10-13 2006-09-19 한국화학연구원 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
JP4557685B2 (ja) 2004-11-15 2010-10-06 独立行政法人理化学研究所 蛍光蛋白質
AU2006205920B2 (en) 2005-01-14 2012-11-15 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mGluR5 antagonists
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
CN101203220A (zh) * 2005-06-28 2008-06-18 阿斯利康(瑞典)有限公司 新用途
CN102816157B (zh) 2005-07-26 2016-05-18 比艾尔-坡特拉有限公司 作为comt抑制剂的硝基儿茶酚衍生物
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
WO2007054436A2 (en) 2005-11-08 2007-05-18 F. Hoffmann-La Roche Ag Thiazolo [4 , 5-c] pyridine derivatives as mglu5 receptor antagonists
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
CA2648303C (en) * 2006-04-03 2014-07-15 Astellas Pharma Inc. 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2083921A2 (en) * 2006-09-04 2009-08-05 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
KR101470659B1 (ko) 2006-09-07 2014-12-08 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-4-일 유도체
US8288554B2 (en) 2006-09-08 2012-10-16 Actelion Pharmaceuticals Ltd. Pyridin-3-yl derivatives as immunomodulating agents
EP2069318B1 (en) 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
LT2481410T (lt) 2007-01-31 2016-11-10 Bial - Portela & Ca., S.A. Nitrokatecholio dariniai kaip komt inhibitoriai vartojami konkrečiu dozavimo režimu
MX2009009597A (es) 2007-03-16 2009-09-16 Actelion Pharmaceuticals Ltd Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
CN102648198B (zh) 2007-08-17 2015-04-01 埃科特莱茵药品有限公司 作为s1p1/edg1受体调节剂的吡啶衍生物
WO2009058298A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain
BRPI0818804A2 (pt) 2007-11-01 2015-04-22 Actelion Pharmaceuticals Ltd Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
CN101903356B (zh) * 2007-12-20 2013-05-22 拜耳知识产权有限责任公司 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
EP2262782B1 (en) 2008-03-07 2012-07-04 Actelion Pharmaceuticals Ltd. Novel aminomethyl benzene derivatives
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
AU2009309019B2 (en) 2008-10-31 2014-11-13 Merck Sharp & Dohme Llc P2X3, receptor antagonists for treatment of pain
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
WO2010111060A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
EP2410857B1 (en) 2009-03-23 2014-01-29 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
WO2010111059A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
US9132094B2 (en) 2009-04-01 2015-09-15 Bial—Portela & Ca, S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
WO2010120741A1 (en) * 2009-04-13 2010-10-21 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
AR077413A1 (es) 2009-07-16 2011-08-24 Actelion Pharmaceuticals Ltd Derivados piridin-4-ilo
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
ES2544086T3 (es) 2011-01-19 2015-08-27 Actelion Pharmaceuticals Ltd. Derivados de 2-metoxi-piridin-4-ilo
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CA2858025C (en) 2011-12-13 2020-09-22 Bial-Portela & Ca., S.A. 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-2-hydroxy-3-methoxy-1-nitrobenzene as an intermediate to prepare a catechol-o-methyltransferase inhibitor
JP5946288B2 (ja) * 2012-02-24 2016-07-06 公立大学法人名古屋市立大学 新規ヒドロキサム酸誘導体及びその用途
BR112015019643A8 (pt) 2013-02-15 2019-11-05 Monsanto Technology Llc compostos de 3,5-dissubstituído-4,5-di-hidro-1,2,4-oxadiazol, composição nematicida aquosa, semente e método para controlar nematódeos indesejáveis
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
US10385043B2 (en) 2015-05-20 2019-08-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
MX2017016876A (es) 2015-06-23 2018-04-10 Kissei Pharmaceutical Derivado de pirazol o sal farmaceuticamente aceptable del mismo.
JP2019515892A (ja) * 2016-03-30 2019-06-13 シンタクシス・エービー 成熟脳損傷の治療における使用のためのｍＧｌｕＲ５のネガティブアロステリックモジュレーター
BR112020018006A2 (pt) * 2018-04-12 2021-01-12 Bayer Aktiengesellschaft Derivados de n-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1h-1,2,4-triazol-5-il]etil}benzamida e os derivados correspondentes de piridina-carboxamida como pesticidas
KR102276327B1 (ko) * 2019-06-25 2021-07-12 연세대학교 산학협력단 신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물
US20230114241A1 (en) * 2019-09-05 2023-04-13 Trevena, Inc. Methods of treating epilepsy using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1149011B (de) * 1960-04-05 1963-05-22 Hoechst Ag Verfahren zur Herstellung von 3, 5-disubstituierten 1, 2, 4-Oxdiazolen
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
ATE210132T1 (de) * 1995-04-21 2001-12-15 Neurosearch As Benzmidazolverbindungen und ihre verwendung als modulatoren des gabaa-rezeptor-komplexes
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
CN1158264C (zh) * 1997-11-21 2004-07-21 Nps药物有限公司 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂

Also Published As

Publication number Publication date
UA75871C2 (en) 2006-06-15
CN1379775A (zh) 2002-11-13
NZ517221A (en) 2004-01-30
NO20020823L (no) 2002-04-17
CN1313465C (zh) 2007-05-02
BR0013427A (pt) 2002-07-30
HUP0202757A3 (en) 2006-03-28
JP3790472B2 (ja) 2006-06-28
HK1047929A1 (en) 2003-03-14
EE200200079A (et) 2003-06-16
MXPA02001764A (es) 2004-03-19
KR20020038731A (ko) 2002-05-23
WO2001012627A1 (en) 2001-02-22
IL148157A (en) 2007-07-04
HUP0202757A2 (hu) 2002-12-28
CZ2002599A3 (cs) 2002-06-12
EP1210344B1 (en) 2005-10-19
EP1210344A1 (en) 2002-06-05
RU2296127C2 (ru) 2007-03-27
IS6275A (is) 2002-02-18
ES2250177T3 (es) 2006-04-16
ZA200201358B (en) 2003-07-30
IL148157A0 (en) 2002-09-12
BG106493A (en) 2003-01-31
AU6782400A (en) 2001-03-13
JP2003507378A (ja) 2003-02-25
JP2006143746A (ja) 2006-06-08
NO20020823D0 (no) 2002-02-19
RU2296127C9 (ru) 2007-08-27
PL353825A1 (en) 2003-12-01
DE60023318T2 (de) 2006-07-20
DE60023318D1 (de) 2006-03-02
AU780191B2 (en) 2005-03-03
BG65586B1 (bg) 2009-01-30
DK1210344T3 (da) 2006-03-06
KR100875222B1 (ko) 2008-12-19
SK2512002A3 (en) 2002-07-02
NO322460B1 (no) 2006-10-09
ATE307129T1 (de) 2005-11-15
CA2381975A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
CY1105253T1 (el) Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
CY1105907T1 (el) Νεα παραγωγα της 1,2,4 - θειαδιαζολης ως ρυθμιστες υποδοχεως μελανοκορτινης
CY1106405T1 (el) Παραγωγα κουιναζολινης
CY1105078T1 (el) Ανταγωνιστες τεκ
CY1108041T1 (el) Αναστολεις της rho-κινασης
ECSP034640A (es) Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
PA8524401A1 (es) DERIVADOS DE 4-Fenil-piridin
CY1110362T1 (el) Ν-(2-αρυλαιθυλο)βενζυλαμινες ως ανταγωνιστες του 5-ητ6 υποδοχεα
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα
CY1116730T1 (el) Παραγωγα ετεροαρυλ-υποκατεστημενης 1,3-διυδροϊνδολ-2-ονης και φαρμακα που περιεχουν αυτα
DK1263752T3 (da) LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
DE69907476D1 (de) Dibenzothiophene derivate und ihre verwendung
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
PA8527401A1 (es) 7-oxo-piridopirimidinas (ii)